• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
ALEXMED ePosters
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 7 (2025)
Volume Volume 6 (2024)
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 5 (2023)
Volume Volume 4 (2022)
Volume Volume 3 (2021)
Volume Volume 2 (2020)
Volume Volume 1 (2019)
Ghaith, A., Helaly, H., ElkamsHoushy, A., Mostafa Dowidar, M. (2024). THE CLINICAL OUTCOMES OF BOSTON KERATORPROSTHESIS TYPE 1 IN ALEXANDRIA, EGYPT. ALEXMED ePosters, 6(3), 18-19. doi: 10.21608/alexpo.2024.305066.1890
Alaa Atef Ghaith; Hany Helaly; Amr Abdelaal ElkamsHoushy; Mazen Amgad Mostafa Dowidar. "THE CLINICAL OUTCOMES OF BOSTON KERATORPROSTHESIS TYPE 1 IN ALEXANDRIA, EGYPT". ALEXMED ePosters, 6, 3, 2024, 18-19. doi: 10.21608/alexpo.2024.305066.1890
Ghaith, A., Helaly, H., ElkamsHoushy, A., Mostafa Dowidar, M. (2024). 'THE CLINICAL OUTCOMES OF BOSTON KERATORPROSTHESIS TYPE 1 IN ALEXANDRIA, EGYPT', ALEXMED ePosters, 6(3), pp. 18-19. doi: 10.21608/alexpo.2024.305066.1890
Ghaith, A., Helaly, H., ElkamsHoushy, A., Mostafa Dowidar, M. THE CLINICAL OUTCOMES OF BOSTON KERATORPROSTHESIS TYPE 1 IN ALEXANDRIA, EGYPT. ALEXMED ePosters, 2024; 6(3): 18-19. doi: 10.21608/alexpo.2024.305066.1890

THE CLINICAL OUTCOMES OF BOSTON KERATORPROSTHESIS TYPE 1 IN ALEXANDRIA, EGYPT

Article 1, Volume 6, Issue 3, July 2024, Page 18-19  XML
Document Type: Preliminary preprint short reports of original research
DOI: 10.21608/alexpo.2024.305066.1890
View on SCiNiTO View on SCiNiTO
Authors
Alaa Atef Ghaith1; Hany Helaly2; Amr Abdelaal ElkamsHoushy1; Mazen Amgad Mostafa Dowidar email 1
1Department of Ophthalmology, Faculty of Medicine, Alexandria University
2Department of ophthalmology, faculty of medicine, Alexandria university
Abstract
INTRODUCTION
There are nearly 36 million individuals who are blind worldwide, and corneal disease is the fifth most common cause of blindness following cataract, uncorrected refractive error, glaucoma and age-related macular degeneration. According to the 2018 EBAA (Eye Bank Association of America), the most common indication for any corneal transplantation in the United States is endothelial dysfunction while keratoconus and corneal infections are the most common indications in other regions. Although corneal graft survival rates are high in these conditions, the survival rates in eyes with high risk of graft failure are significantly lower and, in some cases, so poor that traditional keratoplasty is not indicated. Professor Claes Dohlman developed the Boston Kerato-prosthesis type 1 at the Massachusetts Eye and Ear Infirmary in the 1970s. Since the FDA approved the Boston Kerato-prosthesis type 1 in 1992, its use has increased tremendously for the last two decades not only in the United States but also in other countries. The most common indication for the Boston Keratoprosthesis in many long-term studies is multiple graft failure with 50–65% of eyes reaching a visual acuity of 20/200 or better at 3 years follow-up and a device retention rate of 80–87.8%.
Keywords
BOSTON; KERATORPROSTHESIS; TYPE 1
Supplementary Files
download Mazen Amgad Mostafa Dowidar.pdf
Statistics
Article View: 68
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.